AI
ACAD icon

Axecap Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Axecap Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.4M Buy
152,910
+16,234
+12% +$388K 2.34% 17
2025
Q4 		$3.65M Sell
136,676
-66,695
-33% -$1.59M 2.25% 14
2025
Q3 		$4.34M Buy
+203,371
New +$4.81M 2.68% 12

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Axecap Investments's ACAD Position: Q1 2026 in Review

Axecap Investments increased its Acadia Pharmaceuticals (ACAD) stake by 12% in Q1 2026, buying an estimated $388K and bringing the position to 152,910 shares worth $3.4M. The position accounts for 2.34% of the portfolio, ranked #17.

Axecap Investments first reported a position in ACAD in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.34M in Q3 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Axecap Investments held 152,910 shares of Acadia Pharmaceuticals worth $3.4M as of Q1 2026.
  • Axecap Investments bought 16,234 Acadia Pharmaceuticals shares in Q1 2026, an estimated $388K.
  • Acadia Pharmaceuticals made up 2.34% of Axecap Investments's portfolio in Q1 2026, its #17 holding.
  • Axecap Investments first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Axecap Investments's Acadia Pharmaceuticals position peaked at $4.34M in Q3 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Axecap Investments's 13F filing for Q1 2026, filed 20 Apr 2026.